Search research articles
Contact Us
Filters
Showing results (791-800 of 826) with videos related to
Page
of 83
Sort By:
JACC. Heart Failure
|
April 26, 2025
Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic Cardiomyopathy
Ahmad Masri, Martin S Maron, Theodore P Abraham, et al.
Circulation
|
September 22, 2025
Treatment Response to Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy: 96-Week Results From the EXPLORER Cohort of the MAVA-Long-Term Extension Cardiac Magnetic Resonance Imaging Substudy
Sara Saberi, Christopher M Kramer, Artur Oręziak, et al.
EMBO Molecular Medicine
|
November 17, 2020
Mutations in GRK2 cause Jeune syndrome by impairing Hedgehog and canonical Wnt signaling
Michaela Bosakova, Sara P Abraham, Alexandru Nita, et al.
Journal of the American College of Cardiology
|
September 1, 2024
Effect of Aficamten on Cardiac Structure and Function in Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM CMR Substudy
Ahmad Masri, Rhanderson N Cardoso, Theodore P Abraham, et al.
Gastroenterology
|
April 30, 2015
Effect of Amitriptyline and Escitalopram on Functional Dyspepsia: A Multicenter, Randomized Controlled Study
Nicholas J Talley, G Richard Locke, Yuri A Saito, et al.
Journal of Cardiac Failure
|
July 20, 2023
Aficamten for Drug-Refractory Severe Obstructive Hypertrophic Cardiomyopathy in Patients Receiving Disopyramide: REDWOOD-HCM Cohort 3
Anjali T Owens, Ahmad Masri, Theodore P Abraham, et al.
The American Journal of Gastroenterology
|
March 15, 2017
Polymorphisms of 5-HTT LPR and GNβ3 825C>T and Response to Antidepressant Treatment in Functional Dyspepsia: A Study from The Functional Dyspepsia Treatment Trial
Yuri A Saito, G Richard Locke, Ann E Almazar, et al.
European Heart Journal
|
March 4, 2026
Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term study
Albree Tower-Rader, Ahmad Masri, Michael E Nassif, et al.
JAMA Cardiology
|
January 19, 2017
Evaluation of Structural Progression in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy
Thomas P Mast, Cynthia A James, Hugh Calkins, et al.
Circulation. Heart Failure
|
November 8, 2025
Effect of Aficamten in Women Compared with Men with Obstructive Hypertrophic Cardiomyopathy in SEQUOIA-HCM
Xiaowen Wang, Maria A Pabon, Tracy T Makuvire, et al.
Page
of 83
Search research articles
Search
Showing results (791-800 of 826) with videos related to
Sort By:
Page
of 83
JACC. Heart Failure
|
April 26, 2025
Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic Cardiomyopathy
Ahmad Masri, Martin S Maron, Theodore P Abraham, et al.
Circulation
|
September 22, 2025
Treatment Response to Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy: 96-Week Results From the EXPLORER Cohort of the MAVA-Long-Term Extension Cardiac Magnetic Resonance Imaging Substudy
Sara Saberi, Christopher M Kramer, Artur Oręziak, et al.
EMBO Molecular Medicine
|
November 17, 2020
Mutations in GRK2 cause Jeune syndrome by impairing Hedgehog and canonical Wnt signaling
Michaela Bosakova, Sara P Abraham, Alexandru Nita, et al.
Journal of the American College of Cardiology
|
September 1, 2024
Effect of Aficamten on Cardiac Structure and Function in Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM CMR Substudy
Ahmad Masri, Rhanderson N Cardoso, Theodore P Abraham, et al.
Gastroenterology
|
April 30, 2015
Effect of Amitriptyline and Escitalopram on Functional Dyspepsia: A Multicenter, Randomized Controlled Study
Nicholas J Talley, G Richard Locke, Yuri A Saito, et al.
Journal of Cardiac Failure
|
July 20, 2023
Aficamten for Drug-Refractory Severe Obstructive Hypertrophic Cardiomyopathy in Patients Receiving Disopyramide: REDWOOD-HCM Cohort 3
Anjali T Owens, Ahmad Masri, Theodore P Abraham, et al.
The American Journal of Gastroenterology
|
March 15, 2017
Polymorphisms of 5-HTT LPR and GNβ3 825C>T and Response to Antidepressant Treatment in Functional Dyspepsia: A Study from The Functional Dyspepsia Treatment Trial
Yuri A Saito, G Richard Locke, Ann E Almazar, et al.
European Heart Journal
|
March 4, 2026
Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term study
Albree Tower-Rader, Ahmad Masri, Michael E Nassif, et al.
JAMA Cardiology
|
January 19, 2017
Evaluation of Structural Progression in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy
Thomas P Mast, Cynthia A James, Hugh Calkins, et al.
Circulation. Heart Failure
|
November 8, 2025
Effect of Aficamten in Women Compared with Men with Obstructive Hypertrophic Cardiomyopathy in SEQUOIA-HCM
Xiaowen Wang, Maria A Pabon, Tracy T Makuvire, et al.
Page
of 83